Early complications and long-term outcome after open surgical treatment of popliteal artery aneurysms: is exclusion with saphenous vein bypass still the gold standard?

J Vasc Surg. 2007 Apr;45(4):706-713; discussion 713-5. doi: 10.1016/j.jvs.2006.12.011.

Abstract

Background: Popliteal artery aneurysms (PAAs) are rare, but thromboembolic complications may result in limb loss. To define complications and outcomes after open surgical repairs, we reviewed our experience.

Methods: Clinical data of patients with PAA seen between 1985 and 2004 at Mayo Clinic, Rochester, Minnesota, were reviewed and outcomes in 289 patients with open revascularization were analyzed. Kaplan-Meier method with log-rank tests, chi(2), and Wilcoxon rank sum tests were used for analysis.

Results: A total of 358 PAAs were treated in 289 patients, consisting of 281 (97%) men and eight (3%) women. There were 133 (46%) unilateral and 156 (54%) bilateral PAAs with a mean diameter of 2.9 cm (range, 1.5 to 9 cm). Abdominal aortic aneurysm (AAA) was more frequent with bilateral than unilateral PAAs (65% [101/156] vs 42% [56/133] P = .001). There were 144 (40%) asymptomatic limbs (group 1), 140 (39%) had chronic symptoms (group 2), and 74 (21%) had acute ischemia (group 3). Great saphenous vein (GSV) was used in 242 limbs (68%), polytetrafluoroethylene (PTFE) in 94 (26%), and other types of graft in 22 (6%). Early mortality was 1% (3/358), all in group 3 (4% [3/74]). Six of seven patients with perioperative myocardial infarctions belonged to group 3 (8%). The 30-day graft thrombosis rate was 4%, with 1% in group 1 (1/144), 4% in group 2 (5/140), and 9% in group 3 (7/74). All six early amputations (8%) were in group 3, five with failed bypass (4 PTFE, 1 GSV). Mean follow-up was 4.2 years (range, 1 month to 20.7 years). The 5-year primary and secondary patency rates were 76% and 87%, respectively, higher with GSVs (85% and 94%) than PTFE (50% and 63%, P < .05). Seven recurrent PAAs (2%) required reintervention. The 5-year freedom from reintervention was 100% after endoaneurysmorrhaphy vs 97% after ligations (P = .03). Five-year limb salvage rate was 97% (85% in group 3). There was no limb loss in group 1 and none in group 2 with GSV. In group 3, preoperative thrombolysis reduced the amputation rate in class II patients with marginally threatened limbs (96% vs 69%, P = .02).

Conclusion: Acute presentation of PAA continues to carry high mortality and cardiac morbidity; although preoperative thrombolysis appears to improve results, the 8% early and 15% late amputation rates remain ominous. Early elective repair is recommended because these patients had no surgical mortality, a low rate of complications, and asymptomatic patients had no limb loss at 5 years. GSV and endoaneurysmorrhaphy continues to be the gold standard for open repair of PAA.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Amputation, Surgical / statistics & numerical data
  • Aneurysm / complications*
  • Aneurysm / drug therapy
  • Aneurysm / mortality
  • Aneurysm / pathology
  • Aneurysm / surgery*
  • Blood Vessel Prosthesis Implantation / adverse effects*
  • Blood Vessel Prosthesis Implantation / instrumentation
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Follow-Up Studies
  • Graft Occlusion, Vascular / epidemiology
  • Graft Occlusion, Vascular / etiology
  • Graft Occlusion, Vascular / prevention & control
  • Humans
  • Ischemia / etiology
  • Ischemia / surgery
  • Kaplan-Meier Estimate
  • Length of Stay / statistics & numerical data
  • Lower Extremity / blood supply
  • Male
  • Middle Aged
  • Minnesota / epidemiology
  • Myocardial Infarction / epidemiology
  • Myocardial Infarction / etiology
  • Polytetrafluoroethylene
  • Popliteal Artery / pathology
  • Popliteal Artery / surgery*
  • Prosthesis Design
  • Prosthesis Failure
  • Recurrence
  • Reoperation
  • Saphenous Vein / transplantation*
  • Severity of Illness Index
  • Thromboembolism / etiology
  • Thromboembolism / surgery
  • Time Factors
  • Treatment Outcome
  • Vascular Surgical Procedures / adverse effects

Substances

  • Fibrinolytic Agents
  • Polytetrafluoroethylene